Sustained Therapeutics is a clinical stage company developing non-opioid locally injected therapeutics for the treatment of pain. Our novel sustained-release drug delivery platform has the potential to provide effective, long-lasting solutions for acute and chronic pain, and can support therapeutics for cancer and other indications. Our product is designed to relieve pain in a highly controlled way over longer periods with fewer side effects than the current standard of care. It has a significant competitive advantage, offering up to four weeks of pain relief from a single injection. It is also non-addictive. A successful Phase I clinical trial demonstrated the feasibility of our approach. Two Phase II studies in pain are underway, one in acute and one in chronic pain. We anticipate completing these studies in Q2 2025. In addition, we have initiated a pivotal Phase II/III study in a second product, an oncology medication with an orphan indication, Upper Tract Urethral Carcinoma.